Amgen (CHIX:AMGD) 5-Year EBITDA Growth Rate: 7.80% (As of Mar. 2026)


CHIX:AMGD Amgen Inc CHIX:AMGD
90 GF Score
Price €285.00
GF Value €325.97
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Amgen 5-Year EBITDA Growth Rate?

Amgen CHIX:AMGD 90 5-Year EBITDA Growth Rate is 7.80% as of Mar. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Amgen's EBITDA per Share for the three months ended in Mar. 2026 was €6.13.

During the past 12 months, Amgen's average EBITDA Per Share Growth Rate was 8.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 11.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 7.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amgen was 386.60% per year. The lowest was 0.60% per year. And the median was 15.35% per year.

Amgen  (CHIX:AMGd) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Amgen 5-Year EBITDA Growth Rate Related Terms

CHIX:AMGD vs GILD, PFE, BMY: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - General subindustry, Amgen's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Amgen's 5-Year EBITDA Growth Rate falls into.


CHIX:AMGD
90GF Score
Amgen Inc CHIX:AMGD
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 7.80% mean?
Amgen (CHIX:AMGD) has a 5-Year EBITDA Growth Rate of 7.80% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Amgen and its competitors.
Is Amgen's 5-Year EBITDA Growth Rate too high?
Amgen's current 5-Year EBITDA Growth Rate is 7.80%. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's 5-Year EBITDA Growth Rate compare to GILD and PFE?
Amgen's 5-Year EBITDA Growth Rate of 7.80% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Amgen and its competitors. Amgen's current 5-Year EBITDA Growth Rate is 7.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 7.80%. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current 5-Year EBITDA Growth Rate is 7.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be undervalued. The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97. GuruFocus considers Amgen to be Modestly Undervalued.

Key valuation signals for CHIX:AMGD:

  • 5-Year EBITDA Growth Rate: 7.80%
  • GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
  • GF Score™: 90/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score

Get the complete analysis for CHIX:AMGD

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.00
Price
€325.97
GF Value